GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quantrx Biomedical Corp (OTCPK:QTXB) » Definitions » Intrinsic Value: Projected FCF

Quantrx Biomedical (Quantrx Biomedical) Intrinsic Value: Projected FCF : $0.00 (As of Jun. 04, 2024)


View and export this data going back to . Start your Free Trial

What is Quantrx Biomedical Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-04), Quantrx Biomedical's Intrinsic Value: Projected FCF is $0.00. The stock price of Quantrx Biomedical is $0.004. Therefore, Quantrx Biomedical's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Quantrx Biomedical's Intrinsic Value: Projected FCF or its related term are showing as below:

QTXB's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.72
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Quantrx Biomedical Intrinsic Value: Projected FCF Historical Data

The historical data trend for Quantrx Biomedical's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantrx Biomedical Intrinsic Value: Projected FCF Chart

Quantrx Biomedical Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.05 -0.06 -0.06 -0.06

Quantrx Biomedical Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.06 -0.06 -0.06 -0.06

Competitive Comparison of Quantrx Biomedical's Intrinsic Value: Projected FCF

For the Medical Instruments & Supplies subindustry, Quantrx Biomedical's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quantrx Biomedical's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Quantrx Biomedical's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Quantrx Biomedical's Price-to-Projected-FCF falls into.



Quantrx Biomedical Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Quantrx Biomedical's Free Cash Flow(6 year avg) = $-0.13.

Quantrx Biomedical's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Sep22)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-0.12736+-2.841/0.8)/78.696
=-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quantrx Biomedical  (OTCPK:QTXB) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Quantrx Biomedical's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.004/-0.0605337244493
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quantrx Biomedical Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Quantrx Biomedical's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Quantrx Biomedical (Quantrx Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
10190 SW 90th Avenue, Tualatin, OR, USA, 97062
Quantrx Biomedical Corp operates towards the development and commercialization of patented mini form pad (PAD) based products. The PAD products are based on the company's non-woven disposable absorbent pad technology and it is involved in the PAD-based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its platforms include inSync(R), Unique(TM), and OEM branded over-the-counter and laboratory testing products.
Executives
Michael S Abrams director 64 RAMSHEAD ROAD, RAYNHAM MA 02767
Patrick T Mooney director C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Robert G. Pinco director 1700 K STREET NW, SUITE 300, WASHINGTON DC 20006
Hayes Arthur H Jr director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Matthew Balk 10 percent owner 229 WEST 60TH STREET, NEW YORK NY 10023
Evan Levine director, 10 percent owner 1517 SAN JACINTO ST., HOUSTON TX 77002
Hayes Arthur Hull Jr director C/O QUANTRX BIOMEDICAL CORPORATION, 100 S. MAIN STREET, SUITE 300, DOYLESTOWN PA 18901
Cindy Horton officer: V.P. of Diagnostics 209 BRITTANY PARK, ANDERSON SC 29621
Sasha Afanassiev officer: Officer 120 GARRISON COURT, LANGHORNE PA 19047
Shalom Hirschman officer: Officer 5240 BLACKSTONE AVENUE, RIVERDALE NY 10471
William H Fleming director, officer: Secretary
Walter W Witoshkin director, officer: President and CEO 321 NORRISTOWN ROAD, SUITE 230, AMBLE PA 19002
Mark Capital Llc 10 percent owner 5173 SEAGROVE PLACE, SAN DIEGO CA 92130
Sherbrooke Partners, Llc 10 percent owner 570 LEXINGTON AVENUE, FLOOR 3, NEW YORK NY 10022
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282

Quantrx Biomedical (Quantrx Biomedical) Headlines

No Headlines